B-intervention	0	10	Lanreotide
I-intervention	11	18	Autogel
O	19	21	90
O	22	24	mg
O	25	28	and
B-condition	29	40	lymphorrhea
O	41	51	prevention
O	52	57	after
O	58	66	axillary
O	67	71	node
O	72	82	dissection
O	83	85	in
O	86	92	breast
O	93	99	cancer
O	99	100	:
O	101	102	a
O	103	108	phase
O	109	112	III
O	113	119	double
O	120	125	blind
O	125	126	,
O	127	137	randomized
O	137	138	,
O	139	146	placebo
O	146	147	-
O	147	157	controlled
O	158	163	trial
O	163	164	.

O	165	168	The
O	169	172	aim
O	173	175	of
O	176	180	this
O	181	186	study
O	187	190	was
O	191	193	to
O	194	200	assess
O	201	204	the
O	205	213	efficacy
O	214	216	of
O	217	227	Lanreotide
O	228	235	Autogel
O	236	238	90
O	239	241	mg
O	242	244	PR
O	245	247	to
O	248	255	prevent
O	256	267	lymphorrhea
O	268	273	after
O	274	282	axillary
O	283	293	dissection
O	294	296	in
O	297	303	breast
O	304	310	cancer
O	310	311	.

O	312	313	A
O	314	319	Phase
O	320	323	III
O	324	330	double
O	330	331	-
O	331	336	blind
O	336	337	,
O	338	348	randomized
O	348	349	,
O	350	357	placebo
O	357	358	-
O	358	368	controlled
O	369	374	trial
O	375	378	was
O	379	388	performed
O	389	396	between
O	397	402	April
O	403	406	1st
O	406	407	,
O	408	412	2008
O	412	413	,
O	414	417	and
O	418	426	December
O	427	431	31st
O	431	432	,
O	433	437	2010
O	437	438	.

O	439	442	The
O	443	450	primary
O	451	459	endpoint
O	460	463	was
O	464	467	the
B-outcome-Measure	468	479	lymphorrhea
I-outcome-Measure	480	486	volume
I-outcome-Measure	487	488	(
I-outcome-Measure	488	490	ml
I-outcome-Measure	490	491	)
I-outcome-Measure	492	494	in
I-outcome-Measure	495	498	the
I-outcome-Measure	499	507	axillary
I-outcome-Measure	508	513	drain
I-outcome-Measure	514	520	during
I-outcome-Measure	521	524	the
I-outcome-Measure	525	530	first
I-outcome-Measure	531	535	four
I-outcome-Measure	536	549	postoperative
I-outcome-Measure	550	554	days
O	554	555	.

O	556	559	The
O	560	569	secondary
O	570	573	end
O	574	580	points
O	581	585	were
O	586	589	the
B-outcome-Measure	590	596	number
I-outcome-Measure	597	599	of
I-outcome-Measure	600	604	days
I-outcome-Measure	605	610	until
I-outcome-Measure	611	619	axillary
I-outcome-Measure	620	625	drain
I-outcome-Measure	626	633	removal
O	633	634	,
B-outcome-Measure	635	643	hospital
I-outcome-Measure	644	648	stay
I-outcome-Measure	649	657	duration
I-outcome-Measure	658	659	(
I-outcome-Measure	659	663	days
I-outcome-Measure	663	664	)
O	664	665	,
B-outcome-Measure	666	677	lymphorrhea
I-outcome-Measure	678	684	volume
I-outcome-Measure	685	686	(
I-outcome-Measure	686	688	ml
I-outcome-Measure	688	689	)
O	690	692	up
O	693	695	to
O	696	700	days
O	701	703	15
O	703	704	,
O	705	707	30
O	708	711	and
O	712	715	180
O	715	716	,
B-outcome-Measure	717	723	number
I-outcome-Measure	724	726	of
I-outcome-Measure	727	732	cases
I-outcome-Measure	733	737	with
I-outcome-Measure	738	744	seroma
I-outcome-Measure	745	755	aspiration
I-outcome-Measure	756	759	and
I-outcome-Measure	760	766	number
I-outcome-Measure	767	769	of
I-outcome-Measure	770	776	seroma
I-outcome-Measure	777	788	aspirations
O	788	789	,
B-outcome-Measure	790	800	evaluation
I-outcome-Measure	801	803	of
I-outcome-Measure	804	809	wound
O	809	810	,
B-outcome-Measure	811	814	arm
I-outcome-Measure	815	819	pain
O	820	823	and
B-outcome-Measure	824	832	mobility
O	833	835	on
O	836	840	days
O	841	843	15
O	843	844	,
O	845	847	30
O	848	851	and
O	852	855	180
O	855	856	.

O	857	858	A
O	859	864	total
O	865	867	of
B-total-participants	868	871	148
O	872	880	patients
O	881	885	were
O	886	895	recruited
O	896	899	for
O	900	903	the
O	904	909	study
O	909	910	.

O	911	921	Altogether
B-total-participants	922	925	145
O	926	934	patients
O	935	939	were
O	940	950	randomized
O	951	954	and
O	955	963	analysed
O	964	966	on
O	967	969	an
O	970	979	intention
O	979	980	-
O	980	982	to
O	982	983	-
O	983	988	treat
O	989	994	basis
O	994	995	.

O	996	998	On
O	999	1002	the
O	1003	1006	day
O	1007	1013	before
O	1014	1021	surgery
B-control-participants	1022	1024	73
O	1025	1033	patients
O	1034	1042	received
O	1043	1046	the
B-control	1047	1054	placebo
O	1055	1058	and
B-intervention-participants	1059	1061	72
O	1062	1070	patients
O	1071	1079	received
O	1080	1090	lanreotide
O	1090	1091	.

O	1092	1094	At
O	1095	1099	four
O	1100	1113	postoperative
O	1114	1118	days
O	1118	1119	,
O	1120	1125	there
O	1126	1129	was
O	1130	1131	a
O	1132	1140	tendency
O	1141	1148	towards
O	1149	1150	a
B-outcome	1151	1160	reduction
I-outcome	1161	1163	of
I-outcome	1164	1167	the
I-outcome	1168	1179	lymphorrhea
I-outcome	1180	1186	volume
O	1187	1189	in
O	1190	1193	the
O	1194	1204	lanreotide
O	1205	1210	group
O	1211	1212	(
O	1212	1218	median
B-iv-cont-median	1219	1222	292
I-iv-cont-median	1223	1225	ml
O	1225	1226	,
O	1227	1232	range
O	1233	1234	1
O	1234	1235	-
O	1235	1238	965
O	1239	1241	ml
O	1241	1242	)
O	1243	1245	as
O	1246	1254	compared
O	1255	1257	to
O	1258	1261	the
O	1262	1269	placebo
O	1270	1275	group
O	1276	1277	(
O	1277	1283	median
B-cv-cont-median	1284	1287	337
I-cv-cont-median	1288	1290	ml
O	1290	1291	,
O	1292	1297	range
O	1298	1299	0
O	1299	1300	-
O	1300	1304	1230
O	1305	1307	ml
O	1307	1308	)
O	1308	1309	,
O	1310	1318	although
O	1319	1321	it
O	1322	1325	was
O	1326	1329	not
O	1330	1343	statistically
O	1344	1355	significant
O	1356	1357	(
O	1357	1358	p
O	1359	1360	=
O	1361	1362	0
O	1362	1363	.
O	1363	1365	18
O	1365	1366	)
O	1366	1367	.

O	1368	1373	There
O	1374	1377	was
B-outcome	1378	1380	no
I-outcome	1381	1392	significant
I-outcome	1393	1403	difference
I-outcome	1404	1407	for
I-outcome	1408	1411	the
I-outcome	1412	1421	secondary
I-outcome	1422	1425	end
I-outcome	1426	1432	points
O	1432	1433	.

O	1434	1436	In
O	1437	1440	the
O	1441	1446	group
O	1447	1451	with
O	1452	1460	axillary
O	1461	1471	dissection
O	1472	1481	performed
O	1482	1487	alone
O	1488	1489	(
O	1489	1490	n
O	1491	1492	=
O	1493	1495	24
O	1495	1496	)
O	1496	1497	,
O	1498	1501	the
B-outcome	1502	1513	lymphorrhea
I-outcome	1514	1520	volume
O	1521	1524	was
O	1525	1530	shown
O	1531	1533	to
O	1534	1536	be
O	1537	1550	significantly
O	1551	1558	reduced
O	1559	1561	in
O	1562	1565	the
O	1566	1576	lanreotide
O	1577	1582	group
O	1582	1583	,
O	1584	1585	(
O	1585	1586	p
O	1587	1588	=
O	1589	1590	0
O	1590	1591	.
O	1591	1594	035
O	1594	1595	)
O	1596	1598	as
O	1599	1607	compared
O	1608	1610	to
O	1611	1614	the
O	1615	1622	placebo
O	1623	1628	group
O	1628	1629	.

O	1630	1633	Our
O	1634	1639	study
O	1640	1643	did
O	1644	1647	not
O	1648	1656	identify
O	1657	1660	any
O	1661	1668	overall
O	1669	1680	significant
O	1681	1690	reduction
O	1691	1693	of
O	1694	1705	lymphorrhea
O	1706	1708	on
O	1709	1719	lanreotide
O	1719	1720	.
